Treatment of acute lymphoblastic leukemia in children by ALL IC-BFM 2002 protocol: results of multicenter retrospective study

By the whole history of pediatric acute lymphoblastic leukemia (ALL) treatment protocols development, one of the World ideologist of original science-based therapeutic approaches was German group BFM (Berlin–Frankfurt–Münster). It is not surprisingly that modern ALL treatment protocols, developed by BFM group are high-effective and use in many countries. Understanding the probability of recovery of overwhelming ALL patients majority treated by ALL IC-BFM 2002 protocol, the Scientific-Practical Board of Ministry of Health of Russia in 2020 adopted a protocol as clinical recommendation for pediatric ALL treatment (ID:529).
It the current issue BFM ALL treatment protocols evolution is presented and first Russian multicenter experience in pediatric ALL treatment by ALL IC-BFM 2002 protocol.
It was 408 pediatric and adolescents patients with primary ALL included the study. All of them were treated by ALL IC-BFM 2002 protocol from 01.11.2003 to 12.05.2021. Survival rate was estimated on 01.06.2021.
ALL IC-BFM 2002 demonstrated a high efficiency in multicenter retrospective study. 15-year event-free survival was 83.7 ± 2.1 %, relapsefree survival – 88 ± 1.8 % and overall survival – 93.4 ± 1.4 %. So, ALL IC-BFM 2002 protocol could be realized in Russian clinics and give results similar to world’s leading medical centers.

1. Румянцев А.Г. Эволюция лечения острого лимфобластного лейкоза у детей: эмпирические, биологические и организационные аспекты. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2015;14(1):5–15. [Rumyantsev A.G. Evolution of treatment of acute lymphoblastic leukemia in children: empirical, biological and organizational aspects. Voprosy gematologii/ onkologii i immunopatologii v pediatrii = Pediatric Hematology/ Oncology and Immunopathology 2015;14(1):5–15. (In Russ.)].

2. Pinkel D. History and development of total therapy for acute lymphocytic leukemia. In: Leukemia research: advances in cell biology and treatment. Murphy S.B., Gilbert J.R., eds. New York: Elsevier Science Publishing, 1983. Pp. 189–201.

3. Aur R.J., Simone J., Hustu H.O., Walters T., Borella L., Pratt C., Pinkel D. Central nervous system therapy and combination chemotherapy in childhood lymphocytic leukemia. Blood 1971;37(3):272–81.

4. Riehm H., Gadner H., Henze G. Acute lymphoblastic leukemia: treatment in three BFM studies (1970–1981). In: Leukemia research: advances in cell biology and treatment. Murphy S.B., Gilbert J.R., eds. New York: Elsevier Science Publishing, 1983. Pp. 251–63.

5. Langermann H.J., Henze G., Wulf M., Riehm H. Estimation of tumor cell mass in childhood acute lymphoblastic leukemia: prognostic significance and practical application. Klin Padiatr 1982;194(4):209–13. doi: 10.1055/s-2008-1033807.

6. Riehm H., Feickert H.J., Schrappe М., Henze G., Schellong G. Therapy results in five ALL-BFM studies since 1970: implications of risk factors for prognosis. Haematol Blood Transfus 1987;30:139–46. doi: 10.1007/978-3-642-71213-5_21.

7. Moricke A., Zimmermann M., Reiter A., Henze G., Schrauder A., Gadner H., Ludwig W.D., Ritter J., Harbott J., Mann G., Klingebiel T., Zintl F., Niemeyer C., Kremens B., Niggli F., Niethammer D., Welte K., Stanulla M., Odenwald E., Riehm H., Schrappe M. Longterm results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010;24(2):265–84. doi: 10.1038/leu.2009.257.

8. Sullivan М.P., Chen Т., Dyment P.G., Hvizdala E., Steuber C.P. Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: a Pediatric Oncology Group study. Blood 1982;60(4):948–58. PMID: 6956376.

9. Bleyer W.A., Coccia P.F., Sather H.N., Level C., Lukens J., Niebrugge D.J., Siegel S., Littman P.S., Leikin S.L., Miller D.R. Reduction of central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. J Clin Oncol 1983;1(5):317–25. doi: 10.1200/JCO.1983.1.5.317.

10. Meadows A.T., Baum E., Fossati-Bellani F., Green D., Jenkin R.D., Marsden B., Nesbit M., Newton W., Oberlin O., Sallan S.G. Second malignant neoplasms in children: an update from the Late Effects Study Group. J Clin Oncol 1985;3(4):532–8. doi: 10.1200/JCO.1985.3.4.532.

11. Conter V., Aricò M., Basso G., Biondi A., Barisone E., Messina C., Parasole R., De Rossi G., Locatelli F., Pession A., Santoro N., Micalizzi C., Citterio M., Rizzari C., Silvestri D., Rondelli R., Lo Nigro L., Ziino O., Testi A.M., Masera G., Valsecchi M.G. Longterm results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Associazione Italiana di Ematologia ed Oncologia Pediatrica. Leukemia 2010;24(2):255–64. doi: 10.1038/leu.2009.250.

12. Volejnikova J., Jarosova M., Pospisilova D., Novak Z., Vrbkova J., Hajduch M., Mihal V. Treatment and prognosis of childhood acute lymphoblastic leukemia on protocols ALL-BFM 90, 95 and ALL IC-BFM 2002: a retrospective single-center study from Olomouc, Czech Republic. Neoplasma 2016;63(3):456–61. doi: 10.4149/316_150910N482.

13. Demidowicz E., Pogorzała M., Łęcka M., Żołnowska H., Marjańska A., Kubicka M., Kuryło-Rafińska B., Czyżewski K., Dębski R., Kołtan A., Richert-Przygońska M., Styczyński J. Outcome of Pediatric Acute Lymphoblastic Leukemia: Sixty Years of Progress. Anticancer Res 2019;39(9):5203–7. doi: 10.21873/anticanres.13717.